{"entity":{"id":"fgf23","kind":"target","name":"FGF23","aka":["fibroblast growth factor 23","Fibroblast growth factor 23"],"tldr":"FGF23 (Fibroblast growth factor 23) is a protein on the cell surface. The public catalogues list it as a drug target and an antigen, and an approved or late-stage drug is recorded against it.","summary":"Regulator of phosphate homeostasis. Inhibits renal tubular phosphate transport by reducing SLC34A1 levels. Up-regulates EGR1 expression in the presence of KL.\n\nOpen Targets scores its association with cancer at 0.63 (direct and indirect evidence; datatypes literature 0.90, affected pathway 0.98, animal model 0.53). In OnCo, 1 product record names it (Burosumab).","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:3680","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3680"},{"label":"UniProt Q9GZV9","url":"https://www.uniprot.org/uniprotkb/Q9GZV9/entry"},{"label":"NCBI Gene 8074","url":"https://www.ncbi.nlm.nih.gov/gene/8074"},{"label":"Ensembl ENSG00000118972","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000118972"}],"tags":["cancer-genes-wave"],"related":["open-targets"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["burosumab"],"companies":[],"institutions":[],"pathways":["fgfr-signalling"],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: 1 OnCo product record names it; a membrane or secreted protein (UniProt keywords) that 1 antibody-based OnCo product name. Evidence tier \"approved-drug\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"FGF23","role":["drug-target","antigen"],"evidenceTier":"approved-drug","sources":[{"label":"HGNC HGNC:3680","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3680","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt Q9GZV9","url":"https://www.uniprot.org/uniprotkb/Q9GZV9/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"Open Targets ENSG00000118972","url":"https://platform.opentargets.org/target/ENSG00000118972/associations","note":"association with cancer (MONDO_0004992) 0.63;  (GraphQL API, CC0)"}],"specificity":"tumour-associated","distribution":"few-types","specificityNote":"Tumour-associated overexpression: 1 antibody (Burosumab) aim at the antigen, which HPA finds with no normal tissue stained high; the medicine relies on the tumour carrying more of it than the normal tissue it shares it with. HPA FGF23: RNA tissue enhanced (heart muscle 5 nTPM, liver 5 nTPM); blood lineage lineage enriched (granulocytes 9 nTPM); no normal tissue stained high. Distribution: no corpus cancer carries a prevalence row, threshold or catalogue link for it; Open Targets associates it with 2 specific cancer types at or above 0.5 (tumoral calcinosis, hyperphosphatemic, familial, 2, familial hyperphosphatemic tumoral calcinosis/hyperphosphatemic hyperostosis syndrome). (Rule 5 of scripts/fetch-target-specificity.ts.)","specificitySources":[{"label":"Human Protein Atlas FGF23 tissue","url":"https://www.proteinatlas.org/ENSG00000118972-FGF23/tissue","note":"RNA tissue and blood lineage specificity, normal tissue antibody staining (version 25.1, CC BY-SA 3.0)"},{"label":"Human Protein Atlas FGF23 pathology","url":"https://www.proteinatlas.org/ENSG00000118972-FGF23/pathology","note":"patients per staining level per cancer type (version 25.1, CC BY-SA 3.0)"},{"label":"Open Targets ENSG00000118972 associations","url":"https://platform.opentargets.org/target/ENSG00000118972/associations","note":"cancer associations at or above 0.5 (CC0)"}],"hgnc":"HGNC:3680","ensembl":"ENSG00000118972","uniprot":"Q9GZV9","entrez":"8074","firstDescribed":2000,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: Yamashita et al, Biochem. Biophys. Res. Commun, 2000, \"Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain\".","firstDescribedSource":"https://pubmed.ncbi.nlm.nih.gov/11032749/","biology":"Regulator of phosphate homeostasis. Inhibits renal tubular phosphate transport by reducing SLC34A1 levels. Up-regulates EGR1 expression in the presence of KL. Acts directly on the parathyroid to decrease PTH secretion. Regulator of vitamin-D metabolism. Negatively regulates osteoblast differentiation and matrix mineralisation. Location: Secreted (UniProt). Locus 12p13.32 (HGNC).","whereFound":[],"targetClass":"surface-antigen","prevalence":[]},"route":"/targets/fgf23/","neighbours":{"collection":[{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/"}],"drug":[{"id":"burosumab","kind":"drug","name":"Burosumab","route":"/drugs/burosumab/"}],"pathway":[{"id":"fgfr-signalling","kind":"pathway","name":"FGF / FGFR signalling","route":"/pathways/fgfr-signalling/"}]}}